Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

See all of biopharmadive.com news coverage in one place. Discover how biopharmadive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 216 stories from biopharmadive.com over the past 3 months.

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca · United States

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

48% Center coverage: 103 sources

US bans vaccine ingredient targeted by anti-vaxxers

Robert F. Kennedy Jr. · United States

US bans vaccine ingredient targeted by anti-vaxxers

64% Center coverage: 34 sources

Sarepta Backs Down and Pauses Elevidys Shipments

United States · United States

Sarepta Backs Down and Pauses Elevidys Shipments

50% Center coverage: 20 sources

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion

84% Center coverage: 13 sources

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio. Following the acquisition, Vicebio's non-mRNA candidate vaccine for treating respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) will be added to Sanofi's range.Business · France See the Story

Abivax Stock Soars on Trial Data for Ulcerative Colitis Drug

34% Center coverage: 6 sources

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.Biotech See the Story

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

75% Center coverage: 4 sources

PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Jul 23, 2025-Medical See the Story

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks - Replimune Group (NASDAQ:REPL)

60% Center coverage: 5 sources

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.Stock Markets · United States See the Story

FDA to consider warning against antidepressants

46% Left coverage: 26 sources

(The Center Square) – Doctors on Monday urged the U.S. Food and Drug Administration to issue warnings to pregnant women against the use of certain medications to treat depression, obsessive compulsive disorder and anxiety.Education · United States See the Story

Why Is Alkermes Stock Falling On Monday? - Alkermes (NASDAQ:ALKS)

100% Center coverage: 3 sources

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Narcolepsy is a chronic neurological disorder that disrupts the body’s ability to regulate sleep-wake cycles. It’s characterized by excessive daytime sleepiness and sudden, uncontrollable sleep attacks. Alixorexton, formerly ALKS 2680, is a…See the Story

Apples to apples: Stelara biosimilars and the fight for market share

100% Center coverage: 1 sources

How will payers determine which Stelara biosimilar to add to their formularies?Read Article

From bench to batch: AAV manufacturing for the next-generation of gene therapies

100% Center coverage: 1 sources

Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.Pharma Read Article

Breaking News Topics Related to biopharmadive.com